PSORIASIS

This study looks at the long-term safety and effectiveness of the drug ESK-001 for people with moderate to severe plaque psoriasis. About 1,680 adults who have already been in a prior ESK-001 study will take the drug for 24 weeks, then some may switch to a placebo to see how well…

This study tests whether a single dose of risankizumab (Skyrizi) can clear psoriasis for up to 66 weeks in some patients. Researchers will analyze skin biopsies to understand immune changes that lead to long-term remission. The study involves 20 adults with moderate-to-severe pla…

This study follows 135 children aged 6 to 17 with moderate to severe plaque psoriasis who are taking ustekinumab. Researchers monitor for serious infections, cancer, and autoimmune problems, as well as effects on growth and puberty. The goal is to understand the drug's long-term …

This study tests a drug called guselkumab for children and teens (ages 6 to 17) with chronic plaque psoriasis, a skin condition causing red, scaly patches. About 120 participants receive either the study drug, a placebo, or an active comparator to see how well it clears the skin …

This early-stage study tests a new injectable drug called CMAB015, which is similar to the approved psoriasis treatment Cosentyx. It involves 114 healthy Chinese men to compare how the body processes the drug, its safety, and whether it triggers an immune response. The goal is to…

This study tests whether adding a weight-loss drug (tirzepatide) to a standard psoriasis drug (ixekizumab) helps people with both moderate-to-severe plaque psoriasis and obesity or overweight. About 250 adults will receive either ixekizumab alone or both drugs together for up to …

This study tracks how well risankizumab works for adults recently diagnosed with moderate plaque psoriasis (within the last 2 years) who haven't tried advanced treatments before. About 250 people in Greece will receive the drug as prescribed by their doctor and be observed for up…

This study watches for side effects in 881 people with rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, or psoriasis who receive Remsima under the skin. It aims to see how safe the injection is over time. Participants must have active disease that didn't respond…

This study tests a single dose of brodalumab in children aged 6 to 17 with severe plaque psoriasis. The goal is to check safety and how the drug works in the body. Only 2 children are enrolled, so results are very early.

This study looks at the long-term safety and effectiveness of the drug deucravacitinib for people with moderate-to-severe plaque psoriasis. Participants had already been in earlier studies of this drug. The study also checks how well the drug works with certain vaccines. About 1,…

This study tests whether a dedicated care coordinator can help people with psoriasis or psoriatic arthritis lower their risk of heart disease. About 520 adults aged 40-75 who are not already on cholesterol medication will receive support to manage risk factors like high cholester…

This study tests whether a TENS device, which uses mild electrical pulses, can reduce pain from biologic injections in people with psoriasis. About 20 adults will receive one injection without TENS and another with TENS, then rate their pain. The goal is to find a simple way to e…

This Canadian study follows about 394 adults with plaque psoriasis who are starting brodalumab as part of their regular care. Over 12 months, researchers measure changes in quality of life, work productivity, and treatment satisfaction using simple questionnaires. The goal is to …

This early study tests a special microbubble bath (Thera-Clean) that uses no chemicals to clean skin, reduce itch, and help wounds heal. About 20 people aged 2 and older with epidermolysis bullosa, ichthyosis, atopic dermatitis, or psoriasis will use the bath at home for 8 weeks.…

This study tests whether a daily pill called IRX4204 can safely improve symptoms of mild to moderate plaque psoriasis in adults. About 20 participants will take the drug or a placebo for 28 days and have weekly checkups. The goal is to see if the drug clears or nearly clears skin…

This study aimed to understand why psoriasis and lichen planus often appear where skin is irritated, like from tight clothing. Researchers planned to irritate a small area of skin and take samples to study the inflammation. The study was withdrawn before enrolling anyone, so no r…

This study watches adults with moderate-to-severe psoriasis who are taking brodalumab or other psoriasis medications to see how safe they are over time. Researchers are especially looking for any new cancers. About 3,500 people will take part, and the study just observes their re…

This study is creating a large registry of 15,000 adults and children with inflammatory skin conditions like eczema, psoriasis, and vitiligo. Researchers will follow participants in regular clinics to see how well current and new treatments work and what side effects occur. The g…

This study looks at why psoriasis tends to return even after skin looks healed. Researchers think special immune cells (tissue-resident memory T cells) may act like a 'memory' of the disease. They are testing whether combining a medicated foam (Enstilar®) with narrow-band UVB lig…

This early-stage study tests a single dose of SHR-1139 in 24 healthy adults to check its safety, how the body processes it, and whether it triggers an immune response. It is a first step toward a possible treatment for psoriasis. No direct benefit is expected for participants.

This study looks at medical records from over 1,200 adults with psoriasis to find who is most likely to develop insulin resistance, a condition that can lead to diabetes and heart disease. Researchers will use machine learning to build a simple tool that helps doctors estimate a …

This study is a large registry that will follow about 10,000 adults with psoriasis to see how well different treatments work and what side effects they cause in everyday medical practice. Researchers will track serious health events like infections, heart problems, and cancer. Th…

This study looks at how the drug tildrakizumab helps people with moderate to severe plaque psoriasis. Researchers will take small skin samples from three patients before and after treatment to see how immune cells change. The goal is to understand why the drug works and how long …

This study looks at how well 40 people with moderate-to-severe psoriasis follow their deucravacitinib treatment. Half of the participants will use a special reporting system to help them stay on track, while the other half will not. Researchers will interview patients and use ele…

This study is a large registry that follows over 15,000 people with psoriasis to monitor the long-term safety of several treatments, including biologic drugs like infliximab, ustekinumab, and guselkumab. Participants receive their usual care while researchers track side effects, …